Wegovy benefits consistent regardless of frailty level

Дата публикации: 17-09-2026 13:41:39

In a new analysis of the SELECT trial published in JAMA Cardiology, semaglutide 2.4 mg improved clinical outcomes compared with placebo regardless of frailty level.For the analysis, the 17,604 patients (mean age, 61.6 years; 72.3% men) from SELECT, a trial that demonstrated semaglutide 2.4 mg (Wegovy, Novo Nordisk) reduced risk for major cardiovascular outcomes by 20% compared with placebo, were stratified into three categories according to a 31-item frailty index: not frail (31%), more frail (47%) and most frail (22%).“Practice is currently highly variable, which is due, in part, to

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Scientists discover why Ozempic and Wegovy weight loss eventually plateaus	0	12.8	25-05-2026
2	Eli Lilly's Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity	2	7	31-07-2025
3	Ozempic & Wegovy: Tablette als Alternative? Studie zeigt beeindruckenden Effekt	0	7.03	19-08-2026
4	Замедляет ли "Оземпик" процесс старения, рассказал ученый из МФТИ	0	7.6	22-09-2026
5	Weight loss drugs may literally be saving people's arms and legs	5	7	06-07-2026
6	Dr. Reddy’s to delay semaglutide supplies due to quality issue, shares hit	-2	6	09-07-2026
7	New evidence supports possible anticancer effects with GLP-1s	0	9.55	18-09-2026
8	A New Understanding of HFpEF in Severe Obesity	0	7.54	23-06-2026
9	FDA OKs drug-eluting balloon for coronary in-stent restenosis	0	13.32	22-09-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 13.93. Источник: www.healio.com.